Table 2.
Plasma concentrations of endoglin, PlGF, and MR-proADM in controls and women with severe preeclampsia.
| Control | PE | p valuea | |
|---|---|---|---|
| Endoglin (ng/mL) | 16.5 ± 9.6 (2.2-32.0) (n=17) | 25.3 ± 13.1 (4.2-46.4) (n=12) | 0.046 |
| PlGF (pg/mL) | 317.3 ± 211.7 (15.1-784.4) | 113.4 ± 120.1 (5.9-406.4) (n=11) | 0.007 |
| MR-proADM (nmol/L) | 1.6 ± 0.6 (0.8-2.9) | 1.2 ± 0.5 (0.3-2.0) | 0.041 |
Data are presented as mean ± standard deviation (range). Plasma samples that were too concentrated or too dilute to be detected within the range of the ELISA standard curve for endoglin and PlGF, respectively, were excluded from analysis. Grubbs' test detected one significant outlier in the PlGF concentrations in the PE group; this outlier was also excluded from analysis.
a
Student's t-test.